Hikma Pharmaceuticals PLC (LON:HIK)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 3.18B -25.9% |
| Revenue (ttm) | 2.49B +7.1% |
| Net Income | 298.69M +12.0% |
| EPS | 1.34 +12.4% |
| Shares Out | 214.85M |
| PE Ratio | 11.01 |
| Forward PE | 8.84 |
| Dividend | 0.62 (4.22%) |
| Ex-Dividend Date | Mar 19, 2026 |
| Volume | 682,865 |
| Open | 1,486.00 |
| Previous Close | 1,480.00 |
| Day's Range | 1,473.00 - 1,503.00 |
| 52-Week Range | 1,187.00 - 2,164.00 |
| Beta | 0.64 |
| Analysts | Buy |
| Price Target | 1,899.01 (+27.02%) |
| Earnings Date | Aug 6, 2026 |
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides i... [Read more]
Full Company ProfileFinancial Performance
In 2025, Hikma Pharmaceuticals's revenue was $3.35 billion, an increase of 7.10% compared to the previous year's $3.13 billion. Earnings were $402.00 million, an increase of 11.98%.
Financial numbers in USD Financial StatementsNews
Hikma Pharmaceuticals Transcript: Trading update
Performance is in line with expectations, with robust demand and reiterated 2026 guidance. Strategic focus includes exiting the 503B business, investing in R&D, and expanding capacity. Middle East demand is strong, inflation is managed, and biosimilars lead in MENA.
Hikma Pharmaceuticals Earnings release: Trading update
Hikma Pharmaceuticals released its earnings on April 23, 2026, summarizing the period's financial results.
UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war
Hikma Pharmaceuticals reiterated its 2026 guidance on Thursday, adding that, while it has faced some pressure on shipping, energy, and insurance costs due to the war in the Middle East, a k...
Hikma price target lowered to 1,800 GBp from 2,300 GBp at Berenberg
Berenberg lowered the firm’s price target on Hikma Pharmaceuticals (HKMPF) to 1,800 GBp from 2,300 GBp and keeps a Buy rating on the shares.
Hikma Pharmaceuticals price target lowered to 2,000 GBp from 2,400 GBp at JPMorgan
JPMorgan lowered the firm’s price target on Hikma Pharmaceuticals (HKMPF) to 2,000 GBp from 2,400 GBp and keeps an Overweight rating on the shares.
Hikma Pharmaceuticals Earnings Call Transcript: H2 2025
CEO emphasized long-term growth, decentralization, and heavy R&D investment. Injectables face near-term margin pressure but are set for recovery post-2027, while Rx and MENA divisions drive current growth. $5B revenue target for 2030 remains on track.
Hikma Pharmaceuticals Annual report: H2 2025
Hikma Pharmaceuticals has published its H2 2025 annual report on February 26, 2026.
Hikma Pharmaceuticals Annual report: H2 2025
Hikma Pharmaceuticals has published its H2 2025 annual report on February 26, 2026.
Hikma Pharmaceuticals Slides: H2 2025
Hikma Pharmaceuticals has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 26, 2026.
Hikma Pharmaceuticals Earnings Call Transcript: H2 2025
Revenue grew 6% and core operating profit 3% in 2025, with strong Branded and Hikma Rx performance offsetting margin pressure in Injectables. 2026 guidance targets 2%-4% revenue growth, increased R&D spend, and margin stabilization, with over 250 product launches planned through 2029.
Hikma Pharmaceuticals Annual report: H2 2025
Hikma Pharmaceuticals has published its H2 2025 annual report on February 26, 2026.
Hikma Pharmaceuticals Slides: H2 2025
Hikma Pharmaceuticals has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 26, 2026.
Hikma Pharmaceuticals downgraded to Underweight at Barclays amid uncertainty
As previously reported, Barclays downgraded Hikma Pharmaceuticals (HKMPF) to Underweight from Equal Weight with a 1,600 GBp price target as the firm transferred coverage of European mid-cap pharma to ...
Hikma Pharmaceuticals downgraded to Underweight from Equal Weight at Barclays
Barclays downgraded Hikma Pharmaceuticals (HKMPF) to Underweight from Equal Weight.
Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
Ready-to-use sepsis therapy marks new advancement in time-critical treatment LONDON , Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today an...
Hikma Pharmaceuticals Transcript: Trading Update
Guidance for 2024-2027 is revised to the lower end of revenue and EBIT growth ranges, with injectable margins now guided at 30% due to operational delays and higher R&D. Rx margins are set to approach 20% by 2026, supported by a strong pipeline and CMO growth.
Hikma Pharmaceuticals Earnings release: Trading Update
Hikma Pharmaceuticals released its earnings on November 6, 2025, summarizing the period's financial results.
Hikma Pharmaceuticals tumbles after injectables margin outlook cut
Shares of Hikma Pharmaceuticals fell as much as 10% on Thursday after a strong euro prompted the group to lower margin outlook for its injectables unit, despite beating expectations for overall interi...
Hikma Pharmaceuticals Earnings Call Transcript: H1 2025
Strong revenue growth across all segments, with injectables and branded divisions outperforming and robust R&D investment supporting future pipeline. Margins were impacted by FX and product mix, but guidance and long-term targets remain intact, with significant expansion in contract manufacturing and compounding expected.
Hikma Pharmaceuticals Earnings release: H1 2025
Hikma Pharmaceuticals released its H1 2025 earnings on August 7, 2025, summarizing the period's financial results.
Hikma Pharmaceuticals Slides: H1 2025
Hikma Pharmaceuticals has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 7, 2025.
Hikma Pharmaceuticals Earnings Call Transcript: H1 2025
Strong H1 2025 revenue growth was driven by new launches and the Xellia acquisition, though operating profit declined due to FX and mix effects. Full-year guidance is reiterated, with robust segmental performance and continued investment in capacity and R&D.
Hikma Pharmaceuticals Earnings release: H1 2025
Hikma Pharmaceuticals released its H1 2025 earnings on August 6, 2025, summarizing the period's financial results.
Hikma Pharmaceuticals Slides: H1 2025
Hikma Pharmaceuticals has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 6, 2025.
Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US
Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON , July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today...